The phase 3, double-blind, randomized OlympiA study, which followed 1,800 patients at high risk of recurrence, selected those with the BRCA 1 mutation associated with triple-negative tumors and the BRCA 2 mutation with the highest association. with hormone receptor (HR) positive tumors and previously exposed to chemotherapy. The action of adjuvant olaparib in this subgroup was evaluated.
According to clinical oncologist Maria Cristina Figueroa, from Grupo Oncoclínicas de Curitiba, they were divided into two arms: to receive olaparib at a dose of 300 mg/day or adjuvant placebo for one year, starting 2 to 12 weeks after completing the standard treatment with neoadjuvant or adjuvant chemotherapy and radiotherapy, when indicated. The study results were significant in favor of using olaparib to reduce the risk of incidence. “The gain in invasive disease-free survival was significant, especially when dealing with a disease with a high risk of recurrence. The OlympiA study demonstrated a significant reduction, after one year of olaparib, in invasive recurrences, second malignancies, and distant events,” she comments.
Visit our website and read the full article with all the details of this study, as well as other topics discussed at the ASCO 2021 congress.